S1438
Sulindac sulfone
≥94% (HPLC), (solid or powder)
别名:
(Z)-5-Fluoro-2-methyl-1-[p-(methylsulfonyl)benzylidene]indene-3-acetic acid
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H17FO4S
化学文摘社编号:
分子量:
372.41
MDL编号:
UNSPSC代码:
51111800
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥94% (HPLC)
表单
(solid or powder)
颜色
, Light Yellow to Dark Yellow
溶解性
DMSO: >25 mg/mL
ethanol: 3 mg/mL (warm)
acetone: 5 mg (plus 0.1 ml)
创始人
Merck & Co., Inc., Kenilworth, NJ, U.S.
SMILES字符串
CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C\c3ccc(cc3)S(C)(=O)=O
InChI
1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9+
InChI key
MVGSNCBCUWPVDA-RQZCQDPDSA-N
应用
Human endothelial cells, HMEC-1 were treated with Sulindac sulfone and the effect on cell survival was studied by MTT assay.
生化/生理作用
Metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. Inhibits the development and induces regression of premalignant adenomatous polyps.
Sulindac sulfone is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells1,2 and reduces tumor burden in adenomatous polyposis patients.3
特点和优势
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
制备说明
Sulindac sulfone yields clear, light yellow to dark yellow solution in acetone at 50 mg/ml.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
Jin Kyung Lee et al.
The Journal of pharmacology and experimental therapeutics, 334(2), 410-418 (2010-05-01)
Sulindac is a commonly used nonsteroidal anti-inflammatory drug. This study tested the hypothesis that sulindac-mediated drug-drug interactions and/or hepatotoxicity may be caused, in part, by inhibition of proteins responsible for the hepatic transport of drugs and/or bile acids by sulindac
Tien Hoang et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 1(3), 218-225 (2007-04-06)
The study was designed to evaluate the safety and efficacy of exisulind, a selective apoptotic antineoplastic drug, in combination with gemcitabine as second-line therapy in patients with progressing advanced non-small cell lung cancer. Patients whose disease progressed more than 3
Jun-Yang Liou et al.
Cancer research, 67(7), 3185-3191 (2007-04-06)
To determine the role of 14-3-3 in colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of sulindac on 14-3-3epsilon protein expression in colorectal cancer cells. Sulindac sulfide inhibited 14-3-3epsilon proteins in HT-29 and DLD-1 cells
Gregory A Masters et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 1(7), 673-678 (2007-04-06)
Carboplatin and gemcitabine are one standard regimen for patients with advanced non-small cell lung cancer (NSCLC). The oral proapoptotic agent exisulind is a cyclic guanosine monophosphate phosphodiesterase that increases apoptosis in vitro. We performed a phase II trial of carboplatin
Nis Giladi et al.
Expert opinion on investigational drugs, 19 Suppl 1, S117-S124 (2010-04-14)
The use of sulindac sulfone (SFN) for colorectal cancer (CRC) therapy is limited due to its toxicity. The present study was carried out to examine whether curcumin, a novel chemopreventive agent, can potentiate the effects of low dosages of SFN
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持